Prophylaxis of mycotic infections in immunocompromised patients: a review of 27 reports and publications.
During the last three years, several studies have investigated the potential of ketoconazole for antifungal prophylaxis in immunocompromised patients. Ketoconazole 200 mg o.d. seems to have some effect, but this daily dose is considered too low. Studies using higher doses suggest an increased prophylactic effect with 400 mg and adequate prophylaxis with 600 mg ketoconazole daily. When compared with other antifungals, ketoconazole seems to be superior to nystatin and as effective as amphotericin B (500 mg t.i.d.).
D000666:Amphotericin B / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D007165:Immunosuppression Therapy; D007654:Ketoconazole / Q000008:administration & dosage*; D008825:Miconazole / Q000627:therapeutic use; D009181:Mycoses / Q000517:prevention & control*; D009761:Nystatin / Q000627:therapeutic use
D009761:Nystatin; D008825:Miconazole; D000666:Amphotericin B; D007654:Ketoconazole